TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A study published in Nature Medicine links lower levels of the protective protein NRF2 in oligodendrocytes with abnormal myelin, loss of large nerve fibers and faster cognitive decline. Mouse experiments support a possible causal role, but the findings do not show that an NRF2-targeting drug can prevent age-related decline in people.
Researchers from the University of Edinburgh and the UK Dementia Research Institute report that aging oligodendrocytes—brain cells that maintain nerve fibers’ protective myelin coating—may contribute to cognitive decline when levels of the protective protein NRF2 fall. Published in Nature Medicine, the study combines findings from human brain tissue with mouse experiments, but does not establish a treatment for cognitive decline in people.
The human research drew on the Lothian Birth Cohort 1936, whose participants have had cognitive abilities tracked from childhood into old age. Between ages 70 and 82, researchers assessed memory, processing speed and spatial reasoning. Of the 1,091 people enrolled, 866 completed additional testing after age 70. Most experienced some decline, but the pace differed among individuals.
In brain tissue collected after death from a subset of participants, greater cognitive decline was associated with fewer large nerve fibers and an abnormal buildup of myelin. Myelin insulates nerve fibers and helps electrical signals travel through the brain. The tissue findings were associated with the rate of change in cognition, rather than simply with participants’ test performance at one age.
The researchers found lower NRF2 levels in oligodendrocytes among people with more severe decline. In mice, reducing NRF2 specifically in these cells produced excessive myelin, loss of large nerve fibers and less improvement on cognitive tests as the animals aged. The experiments support a possible direct role for NRF2 loss in cell dysfunction, though animal results cannot establish what will happen in humans.
A Potential Target in Aging Brain Cells
The findings suggest that age-related cognitive change may involve not only damage to neurons, but also problems in the cells that support them. If oligodendrocytes lose some ability to protect themselves and maintain myelin, their normally supportive role could become part of a process that disrupts nerve fibers. The study presents this as a possible contributor to decline, not a complete explanation for it.
The NRF2 pathway is of interest because medications that affect it are already used for other neurological conditions, including multiple sclerosis. That creates a possible route for future research into existing drugs. It does not mean those medications are proven safe or effective for preventing cognitive decline in older adults; clinical testing for that purpose would be needed.
As an affiliate, we earn on qualifying purchases.
From Cohort Records to Mouse Tests
The study’s human component benefits from the cohort’s long record of participants’ cognitive abilities, including assessments at multiple points in later life. That allowed researchers to compare brain tissue findings with changes over time, rather than relying only on a single test score. However, the tissue analysis involved only a subset of the cohort and took place after participants had died.
Oligodendrocytes produce and maintain myelin, and NRF2 regulates genes involved in cellular defenses and normal function. The researchers tested the connection suggested by the human observations by reducing NRF2 in mouse oligodendrocytes. Their findings linked this manipulation with myelin and nerve-fiber changes resembling those in the human tissue. The study therefore brings together an association in people and experimental evidence in animals, which answer different questions and have different limits.
““As the prevalence of cognitive decline is rising with an aging population and no current treatments exist, we are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.””
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital
Human Treatment Evidence Is Missing
The study does not show that reduced NRF2 is the sole cause of cognitive decline, or that increasing NRF2 would reverse the changes in human brains. The tissue analysis is observational, and the mouse experiments cannot establish whether the same effects or treatment response would occur in people. The supplied study account does not specify how large the tissue subset was or provide effect sizes for the reported associations.
It also remains unknown whether an existing drug acting on the NRF2 pathway could be used safely and effectively for age-related cognitive decline. Evidence involving people with multiple sclerosis does not establish a benefit for older adults with cognitive changes from other causes. Researchers would need to determine which patients, if any, might benefit and what outcomes a treatment could change.
Testing the NRF2 Pathway in People
The next steps are to investigate how NRF2 changes affect oligodendrocytes and nerve fibers over time, and to test whether restoring pathway activity can prevent or reduce the observed changes. Before an NRF2-targeting medicine could be considered for age-related cognitive decline, researchers would need evidence from studies in people designed for that purpose, including assessments of safety and cognitive outcomes.
For now, the result identifies a potential biological target and a direction for further research. It does not support changing or starting medication to protect cognition. Whether the pathway can be turned into a useful treatment remains an open question.
Key Questions
What brain cells did the study examine?
It focused on oligodendrocytes, cells that produce and maintain myelin, the insulating coating around nerve fibers.
What is NRF2?
NRF2 is a protein that regulates genes involved in cellular defenses and normal cell function. The study reported lower levels in oligodendrocytes among people with more severe cognitive decline.
Does this prove oligodendrocyte problems cause cognitive decline in people?
No. The human tissue findings show an association. Mouse experiments support a possible causal role, but they do not prove the same process causes decline in people.
Can an existing NRF2-targeting drug prevent age-related cognitive decline?
The study does not establish that. Some drugs affect the pathway for other conditions, but their safety and effectiveness for age-related cognitive decline would need to be tested.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
